





Brain Sci. 2021, 11, x. https://doi.org/10.3390/xxxxx www.mdpi.com/journal/brainsci 
Article 
Expression of Microbial Enzymes in Mammalian Astrocytes to 
Modulate Lactate Release 
Barbara Vaccari Cardoso 1, Iliana Barrera 1, Valentina Mosienko 2, Alexander V. Gourine 3, Sergey Kasparov 1 and 
Anja G. Teschemacher 1,* 
1 School of Physiology, Pharmacology and Neuroscience, University of Bristol, BristolBS8 1TD, UK; b.vaccari-
cardoso@bristol.ac.uk (B.V.C.); iliana.barrera34@gmail.com (I.B.); Sergey.Kasparov@bristol.ac.uk (S.K.) 
2 Institute of Biomedical and Clinical Sciences, College of Medicine and Health, University of Exeter, Exeter 
EX4 4PS, UK; V.Mosienko@exeter.ac.uk  
3 Centre for Cardiovascular and Metabolic Neuroscience, Department of Neuroscience, Physiology & Phar-
macology, University College London, London WC1E 6BT, UK.; a.gourine@ucl.ac.uk  
* Correspondence: Anja.Teschemacher@bristol.ac.uk 
Abstract: Astrocytes support and modulate neuronal activity through the release of L-lactate. The 
suggested roles of astrocytic lactate in the brain encompass an expanding range of vital functions, 
including central control of respiration and cardiovascular performance, learning, memory, execu-
tive behaviour and regulation of mood. Studying the effects of astrocytic lactate requires tools that 
limit the release of lactate selectively from astrocytes. Here, we report the validation in vitro of novel 
molecular constructs derived from enzymes originally found in bacteria, that when expressed in 
astrocytes, interfere with lactate handling. When lactate 2-monooxygenase derived from M. smeg-
matis was specifically expressed in astrocytes, it reduced intracellular lactate pools as well as lactate 
release upon stimulation. D-lactate dehydrogenase derived from L. bulgaricus diverts pyruvate to-
wards D-lactate production and release by astrocytes, which may affect signalling properties of lac-
tate in the brain. Together with lactate oxidase, which we have previously described, this set of 
transgenic tools can be employed to better understand astrocytic lactate release and its role in the 
regulation of neuronal activity in different behavioural contexts. 
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1. Introduction 
The glycolysis product L-lactate (lactate) in the brain has been receiving increasing 
attention as a growing number of studies suggest its roles in the modulation of neuronal 
circuit function as diverse as memory, decision making, response to environmental nov-
elty, depression, central arousal, or autonomic regulation [1–7]. Likewise, where the 
mechanisms of lactate actions have been investigated, these, too, are diverse and are dis-
cussed in the context of meeting metabolic demands by intercellular energy substrate 
shuttling, or receptor-mediated signalling, or modulation of gene expression [4,8–11]. 
Astrocytes can be considered the main source of brain extracellular lactate since they 
are endowed with the machinery to import glucose from the periphery, store energy in 
the form of glycogen, and dynamically shuttle energy substrates throughout the astrocytic 
network and to the extracellular space [12]. Various studies have suggested that astrocytes 
favour the glycolytic pathway over mitochondrial oxidative phosphorylation, resulting in 
excess production and release of lactate [13]. The concentration gradient of lactate, as 
demonstrated for the cortex, is directed from the astrocytic towards the neuronal com-
partment [7,14]. 
In spite of considerable progress and interest in the subject, many questions remain 
open. As an intermediate product in equilibrium-based enzymatic processes that exits its 
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cells of origin in a gradient-driven but also partially regulated manner, the flux of lactate 
through the cellular brain compartments in vivo has proven difficult to match up quanti-
tively with its specific actions on cellular targets and brain circuits. We, therefore, aimed 
to develop a set of molecular tools to support studies into the roles of astrocyte-derived 
lactate in the brain. The rationale was to harness the activity of bacterial enzymes that 
metabolise lactate, and to express them in astrocytes. Our aim was to decrease intra-astro-
cytic lactate pools that can be released to the extracellular space, constitutively or in re-
sponse to local signals, and consequently to reduce lactate action. We recently reported 
that viral vector-mediated expression of bacterial lactate oxidase (LOx) in hippocampal 
astrocytes modulates behaviour in the context of environmental novelty in mice [5]. Here 
we expand the novel toolset by two further constructs, lactate 2-monooxygenase (LMO) 
and D-lactate dehydrogenase (DLDH) and compare the properties between these and LOx 
when expressed in rodent astrocytes. 
LMO, like LOx, irreversibly oxidises lactate into pyruvate at the expense of flavin 
cofactor reduction, which in turn is re-oxidised by molecular oxygen in a 2-step reaction 
[15]. In LOx, pyruvate is released very rapidly from the enzymatic complex, a feature that 
accounts for the fast reaction kinetics of this enzyme [15]. As a result, molecular oxygen, 
which functions as an electron acceptor, forms hydrogen peroxide. LMO activity, on the 
other hand, exhibits higher kinetic stability, which makes pyruvate dissociation from the 
enzymatic complex a significantly slower process [15]. Thus, the reaction of the pyruvate-
enzymatic complex with molecular oxygen culminates in pyruvate decarboxylation, 
yielding acetate and water (Figure 1). We investigated potential differences in the time 
course of action and reactive oxygen species-related effects as these criteria could favour 
the use of one tool over the other for specific applications. 
DLDH catalyses the reversible stereospecific NAD-dependent conversion of py-
ruvate into D-lactate (DL; Figure 1). This was predicted to raise the DL/lactate ratio in 
astrocytes and, subsequently, in the extracellular space. For many lactate-dependent pro-
cesses, DL is a weak substrate and may therefore indirectly impact on lactate-dependent 
processes but, in certain scenarios, e.g., lactate action in the locus coeruleus, DL can act as 
lactate antagonist [4]. 
 
Figure 1. Novel molecular tools based on bacterial enzymes to modulate astrocytic lactate signal-
ling. Astrocytic lactate dehydrogenase (LDH) converts pyruvate from glycolytic activity to lactate. 
Lactate is irreversibly oxidised by transgenic LMO of microbial origin to acetate, or to pyruvate by 
LOx (as previously described in [5]). This decreases the intracellular lactate pool and limits lactate 
release from astrocytes. Bacteria-derived DLDH reversibly catalyses the conversion of pyruvate 
into D-lactate, which is subsequently released from astrocytes. 
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Here we demonstrate the enzymatic activity of viral vector-based expression of LMO 
and DLDH in rat astrocytes in vitro and suggest that the use of these constructs may facil-
itate future studies into the functional roles of lactate in the CNS. 
2. Materials and Methods 
2.1. Vector Construction 
The LMO (E.C. 1.13.12.4) coding sequence from Mycobacterium smegmatis (GenBank: 
AIU22323.1) and the DLDH (E.C. 1.1.1.28) sequence from Lactobacillus delbrueckii subsp. 
bulgaricus (GenBank: WP013438907) were optimised for mammalian codon usage and 
synthesised by Invitrogen ((Life Technologies, Paisley). Expression cassettes were cloned 
to be driven by either CMV, EF1-α or the astrocyte-selective transcriptionally-enhanced 
sGFAP promoter [16]. In addition, an internal ribosomal entry site (IRES), followed by a 
fluorescent marker (EGFP or tdTomato), was included downstream of the LMO or DLDH 
sequence (Figure 2). The cassettes were transferred to an adenoviral vector (AVV) shuttle 
plasmid (pXCX) and vectors derived from type 5 adenovirus were produced as described 
previously [17]. For experiments in HEK293, expression plasmids were transfected using 
TransIT-293 (Mirus, MIR 2700). 
 
Figure 2. Expression of LMO and DLDH in mammalian cells. (a) Domain structure of the cassette 
for transfection of HEK293 cells with LMO and DLDH. The expression was driven by CMV or 
EF1α promoter. Enhanced green fluorescent protein (EGFP) was cloned 3’ of an internal ribosome 
entry site (IRES). (b) A transcriptionally enhanced fragment of GFAP promoter (sGFAP, [16]) was 
employed to selectively target the expression of the enzymes to astrocytes. The bicistronic cas-
settes were introduced into an AVV backbone with tdTomato as a fluorescent marker. (c) Repre-
sentative images of astrocytes in dissociated primary culture (left; scale bar 100 µm) or organo-
typic brainstem slices (right; scale bar 15 µm) transduced with AVV-sGFAP-LMO-IRES-tdTomato. 
(d) Representative images of astrocytes in dissociated primary culture (left; scale bar 60 µm) or 
organotypic brainstem slices (right; scale bar 25 µm) transduced with AVV-sGFAP-DLDH-IRES-
tdTomato. The reporter was amplified by anti-RFP staining. 
To enable assessment of changes in intracellular lactate or pyruvate, AVVs for CMV-
driven expression of the FRET-based reporters for lactate and pyruvate, Laconic and Py-
ronic, respectively, were used [5,18,19]. 
2.2. Astrocyte Cultures 
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Wistar rat pups were sacrificed in accordance with Schedule 1 of the UK Home Office 
(Scientific Procedures) Act (1986) and as approved by the University of Bristol ethics com-
mittees. Primary dissociated astrocytes and organotypic slice cultures were prepared as 
previously described [5,20], and AVVs were added to the culture media. The multiplicity 
of infection (MOI) was determined from the AVV titer (transforming units/ml) as a ratio 
between transforming units added and cell count per culture well. Organotypic cultures 
were transduced with AVV at the time of plating and used 8–12 days later; dissociated 
cultures were transduced at least 2 days before experimentation. 
2.3. Cell Viability Assays 
For estimation of cell viability with the Trypan Blue exclusion assay, astrocytes were 
trypsinised, harvested, and stained with trypan blue 0.4% (Sigma-Aldrich, T8154, Dorset, 
UK). The percentage of blue non-viable cells in the suspension was determined in a 
hemocytometer. For the XTT cell viability assay (Cell Signaling Technology, 9095, Beverly, 
MA, USA), the formazan formation reaction was performed for 2 h. The relative metabolic 
viability of the cells was derived from the sample’s absorbance at 450 nm using a micro-
plate reader (Tecan Infinite M200 PRO, Labtech, Heathfield, UK). 
2.4. Immunohistochemistry 
Primary cultured astrocytes seeded on glass coverslips or brainstem organotypic 
slices excised from the culture membrane were fixed for 15 min in ice-cold 4% paraform-
aldehyde (PFA) in phosphate buffer (PBS; pH 7.4). After rinsing in PBS, the samples were 
incubated for 1 h at room temperature in a solution of 0.3% Triton X-100 (Sigma, T8787) 
and 10% serum. Samples were incubated overnight at 4 °C with anti-RFP antibody (Rock-
land Immunochemicals, 600-401-379S; 1:200, Limerick, PA, USA), rinsed in PBS and incu-
bated for 1 h at room temperature with Alexa Fluor 594 antibody (Thermo Fisher Scien-
tific, R37117, Waltham, MA, USA). 
2.5. Western Blot 
After 72 h of AVV transduction or 3 h of staurosporine (5 µM) treatment, respectively, 
astrocytes were washed twice with cold PBS, treated with RIPA buffer containing protease 
and phosphatase inhibitors (Sigma Aldrich) and harvested. After lysis, cells debris was 
centrifuged at 12,000 rfc and frozen at −80 °C until use. Protein extracts were prepared for 
SDS-PAGE with sample buffer (Invitrogen™ NuPAGE™ LDS Sample Buffer 4X) and re-
ducing agent (Invitrogen™ NuPAGE™ Sample Reducing Agent 10X), then heated for 5 
min to 95 °C. Following protein quantification using Pierce™ BCA Protein Assay Kit, 
equal amounts of protein were run on 10% acrylamide gel (Invitrogen™ NuPAGE™ Bis-
Tris), then transferred to a nitrocellulose membrane (Amersham™ Hybond™) using 
Trans-Blot Cell (Bio-Rad, Watford, UK) and visualised with Ponceau staining (Sigma). 
Membranes were blocked with 2% of ECL blocking reagent in PBS-0.1% Tween 20 (PBS-
T) for 1 h at room temperature, before being incubated overnight at 4 °C with the primary 
antibodies: LDHA (1:2000, Cell Signaling), LDHB (1:1000, Abcam, Cambridge, UK), or 
cleaved caspase 3 antibody (1:1000, Cell Signaling). The same membranes were later incu-
bated with Actin antibody (1:20,000, Sigma). Following three 5 min washing steps in PBS-
T, membranes were incubated for 1 h at room temperature with secondary HRP-linked 
antibodies: Swine anti-rabbit IgG HRP (1:10,000, Dako) or goat anti-mouse IgG HRP 
(1:10,000, Dako). Enhanced Chemiluminescence EZ ECL kit (Geneflow Limited, Lichfield, 
UK) was used for immunodetection. Images were taken with G:BOX (Syngene, Cam-
bridge, UK) operated with GeneSys 1.6.9 software. The quantification of immunoblots 
was performed with Image-J software. Total levels of protein were calculated as the ratio 
of the LDHA or LDHB with actin from the same membrane.  
2.6. Imaging of Intracellular Lactate and Pyruvate 
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Primary cultured astrocytes on glass coverslips expressing Laconic or Pyronic and 
either LMO or DLDH with tdTomato were transferred to a recording chamber on an up-
right confocal microscope (Leica SP1 or SP5) and superfused with HEPES-buffered solu-
tion (HBS; in mM: NaCl 137, KCl 5.4 or 3, Na2HPO4 0.34, KH2PO4 0.44, CaCl2 1.6, MgSO4 
0.8, NaHCO3 4.2, HEPES 10, Glucose 5.5 or 2; pH 7.4; 32.5 ± 1 °C). Laconic or Pyronic were 
excited with the 458 nm line of an Argon ion laser and the emission of mTFP and Venus 
was detected at wavelength 465–500 nm and 515–595 nm, respectively. Images were taken 
every 3 s. Regions of interest were selected and the FRET ratio (mTFP/Venus) was calcu-
lated and normalized to the baseline.  
2.7. Determination of Lactate and DL Release from Dissociated Cultures 
Lactate or DL levels in conditioned media from dissociated cells expressing LMO or 
DLDH were determined with fluorometric assays (BioAssay Systems, EFLLC-100 and 
EFDLC-100, Hayward, CA, USA). HEK293 cells or astrocytes were exposed to serum-free 
culture media for 2 or 6 h, respectively. Samples used for quantification of DL underwent 
deproteination using a 10 kDa spin filter to deplete any potential activity of endogenous 
LDH enzyme. Samples were then processed according to the manufacturer’s instructions 
and fluorescence intensity was measured in a microplate reader (λexcitation: 530 nm, λemission: 
585 nm). Lactate and DL concentrations were calibrated to a standard curve. 
2.8. Determination of Extracellular Lactate in Organotypic Brainstem Slices 
Amperometric lactate biosensors (Sarissa Biomedical, UK, SBS-LAC-05-50, SBI-NUL-
05-50, Coventry, UK) were used for real-time recording of extracellular lactate dynamics 
in organotypic brainstem slices. Slices were transferred to a recording chamber continu-
ously superfused with HBS (see above). The lactate electrode was placed in contact with 
the surface of the slice and allowed to stabilise for at least 30 min. The null electrode was 
positioned on the contralateral side of the slice and its readout was subtracted from the 
current generated by the lactate sensor. 
The potential at the electrode surface was controlled by a potentiostat (Duo-Stat 
ME200+) and the signal was acquired and analysed using a 1401 interface and Spike 2 
software (Cambridge Electronic Design, Cambridge, UK). Known amounts of lactate were 
applied to the chamber at the beginning and at the end of each recording to calibrate the 
electrodes. 
2.9. Statistical Analysis 
Comparison between two experimental groups was made using two-tailed t-tests, 
paired or unpaired, as indicated. Data from three or more groups were compared using 
ANOVA followed by post hoc Tukey’s test or non-parametric Wilcoxon Mann–Whitney 
U test, as indicated. The bars in the scatter plot graphs represent the mean and the error 
bars the standard deviation. Statistical tests were performed using GraphPad Prism soft-
ware. Differences with p < 0.05 between the experimental groups were considered signif-
icant. 
3. Results 
3.1. Potential Negative Effects on the Viability of Astrocytes 
The consequences of interfering with lactate metabolism or outcomes from the pres-
ence of new enzymatic reactions in astrocytes are hard to predict. Therefore, in order to 
identify any cytotoxic effects of the novel tools and to optimise the viral vector titres, pri-
mary cultured astrocytes were transduced with AVV and cell viability was assessed using 
XTT and Trypan Blue exclusion assays. AVV-sGFAP-DLDH-IRES-tdTomato and the con-
trol vector AVV-sGFAP-EGFP did not compromise cell viability in any MOI test (Figure 
3). Transduction with AVV-sGFAP-LMO-IRES-tdTomato did not affect astrocytic viabil-
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ity below an MOI of 50 (Figure 3). All validation experiments in vitro were therefore car-
ried out at MOI 15. Quantification of caspase 3 activation under these conditions showed 
an absence of pro-apoptotic effects of the AVVs on astrocytes (Figure 3c). 
 
Figure 3. Viability of primary cultured astrocytes transduced with LMO and DLDH. Non-trans-
duced astrocytes (No AVV) and astrocytes transduced with AVV-sGFAP-EGFP (Control), AVV-
sGFAP-LMO-IRES-tdTomato (LMO), or AVV-sGFAP-DLDH-IRES-tdTomato (DLDH) at different 
MOIs were compared with regards to cell viability. (a) Trypan Blue exclusion assay; sample sizes n 
= 8 (No AVV), n = 5 (Control MOI15, LMO MOI15, LMO MOI50), n = 6 (Control MOI50, DLDH 
MOI15, DLDH MOI50). (b) XTT assay; sample sizes n = 6 (No AVV), n = 9 all other conditions. 
Cytotoxicity was observed only with transduction of LMO at MOI 50. **** p < 0.0001, * p < 0.05, one 
way ANOVA with Tukey multiple comparison test. (c) Absence of caspase 3 activation in primary 
astrocytes transduced with the novel tools as compared with astrocytes incubated with Stauro-
sporine [5 µM] for 3 h. 
3.2. DLDH Expression Results in Constitutive DL Release 
The enzymatic activity of DLDH cells was assessed through analysis of DL content 
in conditioned media collected from DLDH-expressing cell cultures. HEK293 cells trans-
fected with pTYF-EF1α-DLDH-IRES-EGFP showed a 25.8-fold rise in secreted DL (from 9 
µM in control to 232 µM; Figure 4a). In primary cultured astrocytes transduced with AVV-
sGFAP-DLDH-IRES-tdTomato, DL release increased by 2.6 times as compared to non-
transduced astrocytes (from 3.5 µM in control to 9 µM; Figure 4b). This confirms that 
DLDH expressed in mammalian cells is functional and leads to constitutive DL release. 
 
Figure 4. Constitutive D-lactate release from cells expressing DLDH. (a) Media conditioned by 
non-transfected HEK293 cells (Control, n = 9) and HEK293 cells transfected with 1.5 µg/µl of 
Brain Sci. 2021, 11, x FOR PEER REVIEW 7 of 14 
 
pTYF-EF1α-DLDH-IRES-EGFP (DLDH, n = 9). (b) Media conditioned by non-transduced cultured 
astrocytes (Control, n = 11) and astrocytes transduced with AVV-sGFAP-DLDH-IRES-tdTomato 
(DLDH, n = 13). **** p < 0.0001, unpaired two-tails t-tests. 
3.3. Expression of LMO Reduces Constitutive Lactate Release 
Lactate release from HEK293 cells transfected with pCMV-LMO-IRES-EGFP was re-
duced by 31.6% (Figure 5a), and a reduction of 17.6% was observed in primary cultured 
astrocytes transduced with AVV-sGFAP-LMO-IRES-tdTomato (Figure 5b). Expression of 
DLDH, on the other hand, did not significantly affect constitutive (L-)lactate release (Fig-
ure 5).  
The impact of the astrocyte-selective expression of LMO and DLDH on lactate tone 
was also assessed in organotypic slice cultures using amperometric lactate biosensors. In-
itial contact of the lactate biosensor with the surface of the slice resulted in a current spike 
which declined to a steady-state that reflected constitutive lactate release, i.e., the lactate 
tone (Figure 5c). Transduction of astrocytes in organotypic brainstem slices with AVV-
sGFAP-LMO-IRES-tdTomato resulted in a significantly decreased lactate tone, whereas 
lactate tone in slices transduced with AVV-sGFAP-DLDH-IRES-tdTomato was not af-
fected (Figure 5d). 
 
Figure 5. Effect of LMO or DLDH expression on constitutive lactate release. (a) Lactate concentra-
tion in media conditioned by HEK293 cells transfected with pCMV-IRES-EGFP (Control, n = 6), 
pCMV-LMO-IRES-EGFP (LMO, n = 9), or pTYF-EF1α-DLDH-IRES-EGFP (DLDH, n = 9). (b) Lac-
tate concentration in media conditioned by primary cultured astrocytes transduced with AVV-
sGFAP-EGFP (Control, n = 17), AVV-sGFAP-LMO-IRES-tdTomato (LMO, n = 8), or AVV-sGFAP-
DLDH-IRES-tdTomato (DLDH, n = 11). ** p < 0.01, * p < 0.05, one way ANOVA with Tukey multi-
ple comparison test. (c) Representative trace of an amperometric recording following contact and 
stabilization of the lactate sensor with the surface of the organotypic slice culture. (d) Extracellular 
lactate tone of organotypic cultures transduced with AVV-PRSx8-EGFP alone (Control, n = 14) or 
in combination with AVV-sGFAP-LMO-IRES-tdTomato (LMO, n = 9) or AVV-sGFAP-DHDH-
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IRES-tdTomato (DLDH, n = 13). * p < 0.05, Kruskal–Wallis one-way ANOVA on ranks, followed by 
Dunn’s test. 
3.4. LMO and DLDH Expression in Astrocytes Decreases Evoked Lactate Release 
We next determined the effects of astrocytic expression of LMO and DLDH on the 
release of lactate upon acute stimulation. To force maximal lactate extrusion from cells, 
we stimulated monocarboxylate transporter (MCT) trans-acceleration by bath application 
of a high pyruvate concentration (10 mM), a well-established approach to deplete cells of 
lactate in vitro and in vivo [7,14,19]. By imposing a steep monocarboxylate (pyruvate) gra-
dient, MCT activity is accelerated so that lactate is transported in the opposite direction 
and leaves the cells [21]. 
Bath application of pyruvate evoked a substantial drop in the intracellular concen-
tration of lactate in cultured astrocytes as reported by the FRET sensor Laconic (Figure 
6a). Extracellular lactate levels measured using biosensors in organotypic brainstem slices 
increased transiently in response to pyruvate, indicating lactate release (Figure 6c). In dis-
sociated astrocytes, trans-acceleration-driven lactate release was significantly decreased 
when cells were transduced to express either LMO or DLDH (Figure 6b). The net ampli-
tude of trans-acceleration-driven lactate release from organotypic brainstem slices trans-
duced to express LMO or DLDH in astrocytes exhibited a large variability, precluding the 
detection of any significant effect of LMO and DLDH (Figure 6d). Pyruvate-induced lac-
tate release in organotypic brainstem slices was followed by a transient decrease in lactate 
tone, reaching a minimum that may reflect the transient depletion of intracellular lactate 
pools (Figure 6c; depletion amplitude). This may indicate that newly produced lactate is 
then released to the extracellular space at a reduced rate until intracellular lactate stocks 
are restored to their baseline levels, and the initial tone is re-established. The amplitude 
of lactate depletion triggered by pyruvate was reduced in organotypic brainstem slices 
containing LMO-expressing astrocytes (Figure 6e). 
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Figure 6. Effect of LMO and DLDH on the forced release of lactate. (a) Representative traces of 
Laconic FRET ratio following application of pyruvate [10 mM] in astrocytes expressing AVV-
CMV-Laconic alone (Control) or in combination with AVV-sGFAP-LMO-IRES-tdTomato (LMO) 
or AVV-sGFAP-DLDH-IRES-tdTomato (DLDH). (b) Pooled data of the minimum value from La-
conic FRET ratio following pyruvate application (Control, n = 62; LMO and DLDH, n = 52). **** p < 
0.0001, one way ANOVA with Tukey multiple comparison test. (c) Representative trace of an am-
perometric recording during pyruvate [10 mM] application. (d) and (e) Pooled data for the trans-
acceleration and depletion amplitude, respectively, following pyruvate [10 mM] application in 
organotypic brainstem slices transduced with AVV-PRSx8-EGFP alone (Control, n = 11) or in com-
bination with either AVV-sGFAP-LMO-IRES-tdTomato (LMO, n = 8) or AVV-sGFAP-DLDH-IRES-
tdTomato (DLDH, n = 12). ** p < 0.01, Kruskal–Wallis one-way ANOVA on ranks, followed by 
Dunn’s test. 
3.5. Expression of LMO or DLDH Does not Affect LDH Activity in Astrocytes 
Next, we examined the effects of LMO and DLDH on intracellular pyruvate pro-
cessing in cultured astrocytes using the FRET sensors Pyronic and Laconic. In order to 
exclude constitutive lactate release, we blocked MCT1 with AR-C155858. Both lactate and 
pyruvate built up to a plateau, however, the increase in pyruvate levels were still well 
within the working range of Pyronic. We, therefore, focused on the rate of pyruvate accu-
mulation which was significantly decreased in astrocytes expressing LMO or DLDH, and 
comparable to the effect of LOx (Figure 7a,b; see [5]). These changes were not attributable 
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to altered expression of lactate dehydrogenase (LDH) as shown by stable protein levels of 
both subunits LDHA and LDHB in LMO-, LOx- and DLDH-expressing astrocytes (Figure 
7c). 
 
Figure 7. Intracellular pyruvate build-up upon blockade of MCT1. (a) Time course of the average 
Pyronic FRET ratio upon AR-C155858 [1 µM] application in primary cultured astrocytes trans-
duced with AVV-CMV-Pyronic alone (Control, n = 52) or in combination with either AVV-sGFAP-
LMO-IRES-tdTomato (LMO, n = 69), AVV-sGFAP-DLDH-IRES-tdTomato (DLDH, n = 53), or 
AVV-sGFAP-LOx-IRES-tdTomato (LOx, n = 72). The dotted red lines on the representive slopes 
and the shaded regions around the trace are SEM. (b) Pooled data for the slope of pyruvate pro-
duction; **** p < 0.0001, one way ANOVA with Tukey multiple comparison test. (c) Western blot 
analysis of LDHA and LDHB levels in primary cultured astrocytes expressing LMO, DLDH, and 
LOx; upper—representative blots; lower—quantification of the ratios of LDHA or LDHB to actin 
(n = 7 for all groups). 
4. Discussion 
Studies of lactate-mediated metabolic and signalling interactions between astrocytes 
and neurons have lately been held back by the lack of experimental tools to chronically 
and selectively manipulate the lactate release from astrocytes. To address this issue, we 
developed viral vector-based molecular tools that take advantage of the superior capacity 
of bacteria to metabolise lactate. 
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Both LMO and DLDH are active in many microorganisms where they are involved 
in glycolysis and fermentation. We selected the LMO sequence from Mycobacterium smeg-
matis and the DLDH from Lactobacillus delbrueckii subsp. bulgaricus based on their better 
documented enzymatic activities [15,22]. When adapted to the eukaryotic expression ma-
chinery and expressed in mammalian cells, the activity of the foreign enzymes was con-
firmed.  
A range of factors, such as non-specific side effects of AVV transduction, potential 
trafficking problems associated with the expression of foreign gene products, interference 
with glycolytic pathways, as well as by-products of additional enzymatic processes, can 
all potentially lead to harmful consequences for cells. However, we found that within a 
normal in vitro working range of AVV MOIs, the expression of LMO and DLDH led to 
functional enzymatic activity without causing either measurable detriment or signs of 
apoptotic processes in astrocytes. This was consistent with the expression of the bacterial 
enzyme LOx which we reported earlier, even though LOx enzymatic activity results in 
hydrogen peroxide as a by-product, whereas LMO produces acetate, which is expected to 
be efficiently metabolised further by astrocytes (Figure 1; [5]). In fact, since the data shown 
here and in [5] were obtained in parallel and are based on the same control experiments, 
results from the expression of LMO, DLDH, and LOx are directly comparable. Higher 
levels of LMO, but not DLDH, expression suggested deleterious effects, which may high-
light the importance of maintaining basal lactate or NADH levels for astrocytes. The im-
pact of altered astrocytic lactate metabolism on surrounding brain cells, including neu-
rons, should be assessed in future studies. 
4.1. Lactate Breakdown by LMO 
Many studies have pointed out the importance of lactate for CNS metabolism and 
also, more recently, for brain information processing. Even if it were possible, it would be 
deleterious for cell and tissue function to eliminate lactate pools too drastically. What our 
intervention aimed for and achieved was a modulatory limitation that would decrease the 
amplitude of lactate spikes in response to triggers of astrocytic lactate release [7,14]. These 
are more likely to play relevant roles in activity-dependent lactate signalling.  
As predicted, LMO expression decreased intracellular lactate levels, and this was re-
flected by a reduction of extracellular lactate concentrations in unstimulated conditions, 
as well as reduced pool sizes detected with forced pyruvate-induced extrusion. Therefore, 
in organotypic brainstem slices, we would have expected a reduction in peak lactate re-
lease upon trans-acceleration but were not able to detect a significant change. It is, how-
ever, important to keep in mind that under these conditions, lactate release was forced 
from all MCT-expressing cells in the slice culture - including neurons - and LMO was only 
expressed selectively in astrocytes. Like LMO, LOx also significantly decreased the lactate 
tone in organotypic slices [5]. In contrast to LMO, however, we observed also a decrease 
in lactate release upon pyruvate trans-acceleration [5]. Since LMO and LOx exhibit differ-
ent kinetic properties, with LOx breaking down lactate at approximately a 7000-fold faster 
rate than LMO, this observation may reflect the faster kinetics of LOx [15]. The astrocyte-
selective LMO expression in organotypic slices still significantly affected the maximal 
drop in lactate release after forced extrusion, and this was the case for LOx expression, as 
well [5]. 
We further examined how LMO expression affected the balance of pyruvate and lac-
tate in astrocytes. As expected, when one of the main routes of constitutive lactate export, 
MCT1, was blocked, lactate accumulated in the cells before pyruvate levels started rising 
(not shown). This would apply back-pressure on the LDH reaction until an equilibrium 
between pyruvate and lactate was re-established, consistent with the plateau in the rec-
orded traces. Since the increased lactate levels under these conditions were difficult to 
quantify accurately, we evaluated the rate of pyruvate accumulation as an indirect meas-
ure of lactate build-up when constitutive lactate release was inhibited. The rates of py-
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ruvate accumulation were significantly decreased in LMO-, DLDH- and also LOx-ex-
pressing astrocytes and, considering that LDH expression itself remained unchanged, 
these results are consistent with LMO, LOx, and DLDH activity as an additional lactate 
sink in the cell. 
4.2. DLDH 
Direct recording of DL production in astrocytes was limited as we had no access to 
specific biosensors. Laconic is insensitive to DL [19]. We were able to measure DL in con-
ditioned media and indirectly assess the implications of DLDH activity for astrocytic lac-
tate handling via pyruvate detection. Expression of DLDH significantly raised DL release 
from cells, although the difference with the current version of the construct was modest. 
Through improvements to the expression system, the yield can potentially be increased 
in the future. 
In unstimulated conditions, in dissociated as well as organotypic slice cultures, lac-
tate release was not significantly affected by DLDH activity in astrocytes. Transient dis-
ruption of the lactate/pyruvate/DL equilibrium during trans-acceleration, however, indi-
cated that by diverting pyruvate towards DL synthesis, DLDH had an impact on the 
maintenance of the steady-state lactate pool. 
Endogenous DL production in the brain may occur through the glyoxalase pathway, 
so the brain must be adequately equipped to process this metabolite. Toxic levels as asso-
ciated with short bowel syndrome or in the context of diabetic complications cause DL 
encephalopathy and can interfere severely with brain function [23]. Interestingly, DL has 
also been suggested as a neuroprotective agent in ischemia [24]. 
DL shares various molecular targets, such as transporters and receptors, with lactate. 
For example, MCT1 pumps DL, albeit with a lower affinity and at a slower rate than lac-
tate, or DL activates the lactate receptor HCA1 but with a lower potency than lactate 
[10,25,26]. To our knowledge, a neurophysiological signalling role of DL has not been de-
scribed, although DL is known to interfere with memory, possibly through inhibition of 
cellular respiration or through a receptor-dependent mechanism [27–29].  
With low levels of DL production by astrocytic DLDH expression, we would, there-
fore, not expect any significant actions of DL via the above targets. We have, however, 
previously described DL as a potent antagonist which inhibited lactate-induced stimula-
tion of noradrenaline release from locus coeruleus neurons via an unidentified receptor-
mediated mechanism [4]. For this target, even moderately increased DL levels, as seen 
with our DLDH expression system, could potentially have a significant effect. 
 
5. Conclusions 
In this study, in vitro tests showed that LMO and DLDH are enzymatically active-
when expressed in mammalian astrocytes and are ready for studies requiring modulation 
of lactate, production, release and actions in the brain. 
 
Author Contributions: Conceptualisation, A.G.T.; methodology, A.G.T., S.K., B.V.C., V.M. 
and I.B.; validation, A.G.T. and S.K.; formal analysis and investigation, B.V.C., V.M. and 
I.B.; data curation, B.V.C., A.G.T. and S.K.; writing—original draft preparation, B.V.C. and 
A.G.T.; writing—review and editing, A.G.T., S.K., A.V.G., V.M., I.B. and B.V.C.; visualisa-
tion, B.V.C.; supervision, A.G.T.; resources, project administration and funding acquisi-
tion, A.G.T., A.V.G., S.K. and B.V.C. All authors have read and agreed to the published 
version of the manuscript. 
 
Funding: This research was funded by the British Heart Foundation PG/18/8/33540, 
RG/19/5/34463, by the Conselho Nacional de Desenvolvimento Científico e Tecnológico 
(CNPq) 206427/2014-0 (to B.V.C.) and by the Academy of Medical Sciences Springboard 
Award SBF005n1102 (to V.M.) 
Brain Sci. 2021, 11, x FOR PEER REVIEW 13 of 14 
 
. 
Institutional Review Board Statement The study was conducted according to the guidelines of the 
Declaration of Helsinki and approved by the Ethics Committee of the University of Bristol. 
Data Availability Statement: Data reported in this study are available upon request. Clones are 
available via addgene.org 
Acknowledgements: To L. Arberry and D.J. Carr for expert technical support and A. San Martin 
and L.P. Barros for Laconic and Pyronic constructs.  
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the 
design of the study, in the collection, analyses, or interpretation of data, in the writing of the manu-
script, or in the decision to publish the results. 
References 
1. Alberini, C.M.; Cruz, E.; Descalzi, G.; Bessieres, B.; Gao, V. Astrocyte glycogen and lactate: New insights into learning and 
memory mechanisms. Glia 2018, 66, 1244–1262, doi:10.1002/glia.23250. 
2. Carrard, A.; Elsayed, M.; Margineanu, M.; Boury-Jamot, B.; Fragniere, L.; Meylan, E.M.; Petit, J.M.; Fiumelli, H.; Magistretti, P.J.; 
Martin, J.L. Peripheral administration of lactate produces antidepressant-like effects. Mol. Psychiatry 2018, 23, 392–399, 
doi:10.1038/mp.2016.179. 
3. Marina, N.; Ang, R.; Machhada, A.; Kasymov, V.; Karagiannis, A.; Hosford, P.S.; Mosienko, V.; Teschemacher, A.G.; Vihko, P.; 
Paton, J.F.; et al. Brainstem hypoxia contributes to the development of hypertension in the spontaneously hypertensive rat. 
Hypertension 2015, 65, 775–783, doi:10.1161/HYPERTENSIONAHA.114.04683. 
4. Tang, F.; Lane, S.; Korsak, A.; Paton, J.F.; Gourine, A.V.; Kasparov, S.; Teschemacher, A.G. Lactate-mediated glia-neuronal 
signalling in the mammalian brain. Nat. Commun. 2014, 5, 3284, doi:10.1038/ncomms4284. 
5. Vaccari Cardoso, B.; Shevelkin, A.V.; Terrillion, C.; Mychko, O.; Mosienko, V.; Kasparov, S.; Pletnikov, M.V.; Teschemacher, 
A.G. Reducing l-lactate release from hippocampal astrocytes by intracellular oxidation increases novelty induced activity in 
mice. Glia 2021, 69, 1241–1250, doi:10.1002/glia.23960. 
6. Wang, J.; Tu, J.; Cao, B.; Mu, L.; Yang, X.; Cong, M.; Ramkrishnan, A.S.; Chan, R.H.M.; Wang, L.; Li, Y. Astrocytic l-Lactate 
Signaling Facilitates Amygdala-Anterior Cingulate Cortex Synchrony and Decision Making in Rats. Cell Rep. 2017, 21, 2407–
2418, doi:10.1016/j.celrep.2017.11.012. 
7. Zuend, M.; Saab, A.S.; Wyss, M.T.; Ferrari, K.D.; Hosli, L.; Looser, Z.J.; Stobart, J.L.; Duran, J.; Guinovart, J.J.; Barros,  L.F.; et al. 
Arousal-induced cortical activity triggers lactate release from astrocytes. Nat. Metab. 2020, 2, 179–191, doi:10.1038/s42255-020-
0170-4. 
8. Herrera-Lopez, G.; Galvan, E.J. Modulation of hippocampal excitability via the hydroxycarboxylic acid receptor 1. Hippocampus 
2018, 28, 557–567, doi:10.1002/hipo.22958. 
9. Magistretti, P.J.; Allaman, I. Lactate in the brain: From metabolic end-product to signalling molecule. Nat. Rev. Neurosci. 2018, 
19, 235–249, doi:10.1038/nrn.2018.19. 
10. Mosienko, V.; Rasooli-Nejad, S.; Kishi, K.; De Both, M.; Jane, D.; Huentelman, M.; Kasparov, S.; Teschemacher, A. Putative 
Receptors Underpinning l-Lactate Signalling in Locus Coeruleus. Neuroglia 2018, 1, 365–380, doi:10.3390/neuroglia1020025. 
11. Pellerin, L.; Magistretti, P.J. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal 
activity to glucose utilization. Proc. Natl. Acad. Sci USA 1994, 91, 10625–10629, doi:10.1073/pnas.91.22.10625. 
12. Dienel, G.A. Fueling and imaging brain activation. ASN Neuro 2012, 4, AN20120021, doi:10.1042/AN20120021. 
13. Supplie, L.M.; Duking, T.; Campbell, G.; Diaz, F.; Moraes, C.T.; Gotz, M.; Hamprecht, B.; Boretius, S.; Mahad, D.; Nave, K.A. 
Respiration-Deficient Astrocytes Survive As Glycolytic Cells In Vivo. J. Neurosci. 2017, 37, 4231–4242, 
doi:10.1523/JNEUROSCI.0756-16.2017. 
14. Machler, P.; Wyss, M.T.; Elsayed, M.; Stobart, J.; Gutierrez, R.; von Faber-Castell, A.; Kaelin, V.; Zuend, M.; San Martin, A.; 
Romero-Gomez, I.; et al. In Vivo Evidence for a Lactate Gradient from Astrocytes to Neurons. Cell Metab. 2016, 23, 94–102, 
doi:10.1016/j.cmet.2015.10.010. 
15. Maeda-Yorita, K.; Aki, K.; Sagai, H.; Misaki, H.; Massey, V. L-lactate oxidase and L-lactate monooxygenase: Mechanistic 
variations on a common structural theme. Biochimie 1995, 77, 631–642, doi:10.1016/0300-9084(96)88178-8. 
16. Liu, B.; Paton, J.F.; Kasparov, S. Viral vectors based on bidirectional cell-specific mammalian promoters and transcriptional 
amplification strategy for use in vitro and in vivo. BMC Biotechnol. 2008, 8, 49, doi:10.1186/1472-6750-8-49. 
17. Duale, H.; Kasparov, S.; Paton, J.F.; Teschemacher, A.G. Differences in transductional tropism of adenoviral and lentiviral 
vectors in the rat brainstem. Exp. Physiol. 2005, 90, 71–78, doi:10.1113/expphysiol.2004.029173. 
18. San Martin, A.; Ceballo, S.; Baeza-Lehnert, F.; Lerchundi, R.; Valdebenito, R.; Contreras-Baeza, Y.; Alegria, K.; Barros, L.F. 
Imaging mitochondrial flux in single cells with a FRET sensor for pyruvate. PLoS ONE 2014, 9, e85780, 
doi:10.1371/journal.pone.0085780. 
19. San Martin, A.; Ceballo, S.; Ruminot, I.; Lerchundi, R.; Frommer, W.B.; Barros, L.F. A genetically encoded FRET lactate sensor 
and its use to detect the Warburg effect in single cancer cells. PLoS ONE 2013, 8, e57712, doi:10.1371/journal.pone.0057712. 
Brain Sci. 2021, 11, x FOR PEER REVIEW 14 of 14 
 
20. Teschemacher, A.G.; Paton, J.F.; Kasparov, S. Imaging living central neurones using viral gene transfer. Adv. Drug Deliv. Rev. 
2005, 57, 79–93, doi:10.1016/j.addr.2004.05.004. 
21. Fishbein, W.N.; Foellmer, J.W.; Davis, J.I.; Fishbein, T.M.; Armbrustmacher, P. Clinical assay of the human erythrocyte lactate 
transporter. I. Principles, procedure, and validation. Biochem. Med. Metab. Biol. 1988, 39, 338–350, doi:10.1016/0885-
4505(88)90094-1. 
22. Manome, A.; Okada, S.; Uchimura, T.; Komagata, K. The ratio of L-form to D-form of lactic acid as a criteria for the identification 
of lactic acid bacteria. J. Gen. Appl. Microbiol. 1998, 44, 371–374, doi:10.2323/jgam.44.371. 
23. Kowlgi, N.G.; Chhabra, L. D-lactic acidosis: An underrecognized complication of short bowel syndrome. Gastroenterol. Res. Pr. 
2015, 2015, 476215, doi:10.1155/2015/476215. 
24. Castillo, X.; Rosafio, K.; Wyss, M.T.; Drandarov, K.; Buck, A.; Pellerin, L.; Weber, B.; Hirt, L. A probable dual mode of action for 
both L- and D-lactate neuroprotection in cerebral ischemia. Br. J. Pharmacol. 2015, 35, 1561–1569, doi:10.1038/jcbfm.2015.115. 
25. Cai, T.Q.; Ren, N.; Jin, L.; Cheng, K.; Kash, S.; Chen, R.; Wright, S.D.; Taggart, A.K.; Waters, M.G. Role of GPR81 in lactate-
mediated reduction of adipose lipolysis. Biochem. Biophys. Res. Commun. 2008, 377, 987–991, doi:10.1016/j.bbrc.2008.10.088. 
26. Halestrap, A.P. Monocarboxylic acid transport. Compr. Physiol. 2013, 3, 1611–1643, doi:10.1002/cphy.c130008. 
27. Bozzo, L.; Puyal, J.; Chatton, J.Y. Lactate modulates the activity of primary cortical neurons through a receptor-mediated 
pathway. PLoS ONE 2013, 8, e71721, doi:10.1371/journal.pone.0071721. 
28. Gibbs, M.E.; Hertz, L. Inhibition of astrocytic energy metabolism by D-lactate exposure impairs memory. Neurochem. Int. 2008, 
52, 1012–1018, doi:10.1016/j.neuint.2007.10.014. 
29. Scavuzzo, C.J.; Rakotovao, I.; Dickson, C.T. Differential effects of L- and D-lactate on memory encoding and consolidation: 
Potential role of HCAR1 signaling. Neurobiol. Learn. Mem. 2020, 168, 107151, doi:10.1016/j.nlm.2019.107151. 
 
